Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension.

Area of Science:

• Cardiovascular Research
• Pulmonary Medicine
• Molecular Biology

Background:

• Pulmonary hypertension (PH) affects 1% of the global population, increasing with age.
• It often complicates chronic lung/heart diseases but can also stem from chronic hypoxia, e.g., at high altitudes.
• Sustained hypoxia drives pulmonary vasoconstriction and vascular remodeling, elevating pulmonary arterial pressure.

Purpose of the Study:

• To review the molecular mechanisms of the hypoxia-pulmonary hypertension axis.
• To explore interconnected signaling networks involved in disease pathogenesis.
• To identify knowledge gaps and potential therapeutic targets.

Main Methods:

• Literature review of molecular mechanisms.
• Focus on signaling pathways including redox, PI3K-Akt, NO bioavailability, autophagy, and metabolic reprogramming.
• Emphasis on adventitial remodeling and fibroblast involvement.

Main Results:

• Hypoxia triggers pulmonary vasoconstriction and vascular remodeling.
• Key pathways include redox imbalance, PI3K-Akt signaling, nitric oxide bioavailability, autophagy, mitochondrial dynamics, metabolic reprogramming, inflammation, and adventitial remodeling.
• Erythropoietin signaling is also implicated.

Conclusions:

• The hypoxia-pulmonary hypertension axis is driven by complex, interconnected molecular signaling.
• While therapeutic targets exist, translation to clinical practice remains challenging due to the multifactorial nature of the disease.
• Further research into these integrated pathways is needed for effective treatment development.